

# Intensification of Insulin Therapy for Type 2 Diabetic Patients in Primary Care: Basal-Bolus Regimen Versus Premix Insulin Analogs

## When and for whom?

OFRI MOSENZON, MD  
ITAMAR RAZ, MD

In April 2012, the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) published a joint position statement regarding treatment of hyperglycemia in type 2 diabetes, "Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach" (1). As most diabetic patients (>366 million worldwide) (2) are treated by their primary family physician and not by an endocrinologist or diabetologist, the guidelines were intended to help physicians choose the best treatment for their patients. Some of the advantages of this position statement, over previous guidelines (3–8), are as follows: emphasizing the importance of individualization of treatment, widening treatment options, and stating the pros and cons of the different treatment option. However, as the statement was written by a group of world-known diabetologists, without the input of nurses, dietitians, family physicians, or the patients themselves, questions have been raised as to how "patient-centered" it actually is and how useful and relevant it is to the primary care setting. Choosing the best insulin regimen for initiation and intensification of insulin therapy in type 2 diabetic patients is still debatable both in the specialist clinic and in the primary care setting. The intention of this

article is to review the data available and offer reasonable guidance regarding the selection of the preferred insulin regimen for initiation and intensification of insulin treatment, especially in a primary care setting.

The ADA/EASD statement includes recommendations for the initiation and titration of insulin therapy (1). The recommendations point out three important aspects that need to be addressed when choosing or adjusting insulin regimens: the number of injections needed and the complexity and the flexibility of the regimens. The insulin regimens under consideration include basal insulin, premixed, basal insulin with one premeal short-acting insulin injection (referred to as basal plus regimen), and basal insulin with two or more short-acting insulin injections (basal bolus). In this article, we will attempt to better define the place of premix insulin analogs in comparison with other possible insulin regimens. We will focus on premix insulin analog use in the primary care setting, the benefits and drawbacks of this kind of treatment, its target patient population, and its appropriate use in the various stages of the disease.

### Definition and nomenclature of premixed human insulin and premix insulin analogs

Primary care physicians are often puzzled by the many options available regarding

insulin selection. A better understanding of the pharmacology of the different insulin preparations is necessary in order to insure proper insulin selection. Human soluble insulin exists in a hexameric form in pharmaceutical preparations, which delays its absorption into the bloodstream after subcutaneous injection. The dissociation into the dimer and monomer forms, which are more readily absorbed into the bloodstream, requires the molar concentration of insulin to decrease to  $<10^{-7}$  mol/L and the absence of zinc ions (9). In order to control their postprandial glucose, patients need to inject human insulin at least one-half hour before the meal. Rapid insulin analogs were developed to address this issue, and this was demonstrated in pharmacokinetic and euglycemic clamp studies (10,11). Premix human insulin contains a mixture of two components: human insulin (Humulin R or Actrapid) and the same insulin attached to protamine, which prolongs its absorption so that it becomes intermediate-acting insulin (Humulin N and Insulatard, respectively). Premix insulin analogs are also a mixture of two components: rapid-acting insulin analog (insulin aspart or insulin lispro) and the same rapid-acting insulin analog attached to protamine, which prolongs its absorption so that it transforms into an intermediate-acting insulin with NPH-like pharmacokinetic (10,11). The rapid-acting component of the premix insulin analog is the one that appears in its name, e.g., biphasic insulin aspart 30 includes 30% insulin aspart and 70% intermediate-acting insulin, while biphasic insulin lispro 25 includes 25% lispro and 75% intermediate-acting insulin. Unlike premix human insulin, premix insulin analog can be injected immediately before (12) or right after (13) a meal. Aside from the convenience for the patient, studies that compared the clinical effect gained by uses of premix insulin analog compared with premix human insulin have somewhat conflicting results. While some

From the Diabetes Unit, Department of Internal Medicine, Hadassah University Hospital, Jerusalem, Israel. Corresponding author: Itamar Raz, ntv502@netvision.net.il.

This publication is based on the presentations from the 4th World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy). The Congress and the publication of this supplement were made possible in part by unrestricted educational grants from Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Ethicon Endo-Surgery, Janssen, Medtronic, Novo Nordisk, Sanofi, and Takeda.

DOI: 10.2337/dcS13-2007

© 2013 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See <http://creativecommons.org/licenses/by-nc-nd/3.0/> for details.



studies demonstrated improvement in postprandial glucose (14–20) or HbA<sub>1c</sub> (18,21), others demonstrated reduction in mild hypoglycemia, severe hypoglycemia, or nocturnal hypoglycemia (15,22,23). Several meta-analyses combined the results of some of these studies (24–27). Qayyum et al. (24) concluded that premix insulin analogs provided better postprandial glucose than premixed human insulin, while Davidson et al. (27) concluded that premix insulin analogs provided significant reduction in major hypoglycemic events compared with premix human insulin (0.45 [95% CI 0.22–0.93],  $P < 0.05$ ). The markets in developed countries have switched over the past few years from premix human insulin to premix insulin analogs as well as to other insulin analogs (28,29).

### Initiation of insulin therapy with basal versus premix insulin analogs

During the course of type 2 diabetes, because of the progressive nature of  $\beta$ -cell destruction many patients at some point require insulin therapy (1,30). Most patients and physicians delay starting insulin therapy for several reasons: fear of increased risk of hypoglycemia and weight gain, the “bad reputation” that insulin therapy is a sign of disease progression, fear of dependency on the medication, and other beliefs and myths (31). The primary physician may be even more hesitant to begin insulin therapy than the endocrinologist/diabetologist as a result of lack of knowledge and/or experience with initiation of insulin therapy, lack of a supporting team (nurses, dietitians, diabetes educators, etc.), and lack of time and incentives. The UK Prospective Diabetes Study (UKPDS) 10-year follow-up (32) demonstrated the importance of early diabetes control in order to avoid the accumulation of “bad metabolic memory.” The Outcome Reduction With Initial Glargine Intervention (ORIGIN) Trial (33) was carried out in order to determine whether insulin therapy, using insulin glargine to target fasting normoglycemia (fasting plasma glucose  $\leq 95$  mg/dL [5.3 mmol/L]), compared with standard care can reduce cardiovascular morbidity or mortality in people at high cardiovascular risk with early type 2 diabetes, impaired fasting glucose, or impaired glucose tolerance. The ORIGIN failed to prove its primary end point; however, it did demonstrate the durability, safety, and tolerability of insulin therapy in patients with relatively short diabetes duration (average duration of diabetes  $5.5 \pm 6.1$  and  $5.3 \pm 5.9$  years in the intervention and control groups, respectively)

and even in the prediabetic state ( $n = 1,449$ , 11.6%). The ORIGIN study also demonstrated that in these relatively new-onset diabetic patients, excellent glucose control can be achieved. Most of the patients with short disease duration are treated by primary care physicians, and therefore it is of great importance to support these physicians with all the necessary tools to be able to treat these patients with the best therapy available, including insulin, when necessary. The importance of early glucose control and its influence on patient prognosis cannot be overemphasized; unfortunately, there is often a major delay in the initiation of insulin therapy. Brown et al. (34) have shown in their prospective, population-based study using retrospective observational data that the average patient accumulated nearly 5 years of HbA<sub>1c</sub>  $> 8.0\%$  and  $\sim 10$  years of HbA<sub>1c</sub>  $> 7.0\%$  from diagnosis until initiation of insulin therapy. Insulin therapy is an ongoing process that may be divided into the following steps: 1) setting HbA<sub>1c</sub> goal for a particular patient, 2) initiating insulin therapy, 3) titration of insulin doses to target, and 4) intensification of the insulin regimens if target is not achieved. The role of the primary care health professional team (family physician, nurse, dietitian, etc.) in all of these steps is crucial. Their frequent and easier contact with the patient makes them ideal partners for the difficult mission of ensuring proper insulin use to improve glucose control. Currently, the most common approaches to initiating insulin therapy are with basal insulin analogs, usually at bedtime, or with premix insulin analogs, usually with breakfast and dinner (35). However, as the use of basal insulin analogs (glargine and detemir) as a replacement for NPH insulin became widespread, there is now a greater tendency to use this once-daily and more convenient approach as the first step in insulin therapy.

The first question to address is whether basal insulin therapy is the best way to initiate insulin therapy for all diabetic patients requiring insulin or whether we can identify a group of patients for whom it is better to start insulin therapy with premix insulin analogs.

The results of randomized control studies comparing initial treatment with basal insulin analogs to premix insulin analogs demonstrated mixed results. Most studies demonstrated a higher reduction of HbA<sub>1c</sub> with premix insulin analogs (36–42). However, some studies did not demonstrate statistically significant differences between the two groups (43–46). Increased risk of weight gain (36,40–42) and minor

hypoglycemic events (36,42–44), however, were reported more frequently using premix insulin analogs.

There are many limitations to the above-mentioned group of studies. Most of these studies are small, unblinded, and sponsored by industry.

The 4-T study (40) randomized insulin-naïve patients in an open-labeled, multicenter study to receive either basal insulin (detemir) ( $n = 234$ ) once or, if required, twice daily; prandial short-acting insulin (aspart) ( $n = 239$ ) three times daily; or premix insulin analog (biphasic premix insulin aspart 30) ( $n = 235$ ) twice daily. After a year of treatment, both the prandial and the premix treated groups reached better glucose control (HbA<sub>1c</sub>  $7.2 \pm 0.9$  and  $7.3 \pm 0.9\%$ , respectively,  $P = 0.08$ ) compared with the basal insulin-treated group (HbA<sub>1c</sub>  $7.6 \pm 1.0\%$ ,  $P < 0.001$ ). However, patients in whom HbA<sub>1c</sub> at the beginning of the study was  $< 8.5\%$  achieved similar reduction in HbA<sub>1c</sub> regardless of the insulin regimen. The hypoglycemic events rates and mean weight gained were higher among the prandial group, intermediate in the premix-treated group, and lowest in the basal insulin-treated group (12.0, 5.7, and 2.3 events/patient/year and 5.7, 4.7, and 1.9 kg, respectively,  $P < 0.001$ ).

How meaningful is comparison of one injection a day (often with much lower dose) to two injections? Unfortunately, studies comparing initiation of insulin therapy by basal insulin analogs versus premix insulin analogs did not help to define which patients are better suited to each treatment arm.

A community-based 18-month retrospective observational study collected data from the USA National Medical Records to compare reduction of HbA<sub>1c</sub> in patients who were initiated on basal insulin regimen (glargine,  $n = 3,624$ ) with patients who were initiated with premix insulin ( $n = 4,542$ ) and specifically with premix insulin lispro 25 ( $n = 895$ ) (47). This observational study has shown that both insulin regimens demonstrated a reduction in HbA<sub>1c</sub>. The reduction in HbA<sub>1c</sub> was, however, greater with the combined premix therapy (that included both premix human insulin and premix insulin analogs) (0.04–0.14%;  $P < 0.05$ ) and greatest in the premix lispro 25 group (0.26–0.65%;  $P < 0.05$ ) compared with the basal insulin group. This study was limited, however, since it was supported by industry and was based on a retrospective, nonrandomized cohort analysis with a large and unequal patient



drop-out rate. Its strengths, on the other hand, are the relatively large patient sampling and “real-life” setting. The results of this observational study are supported by a meta-analysis that compared the efficacy of basal versus premix insulin analogs in achieving glucose control in randomized control trials (RCTs) (48). The meta-analysis included RCTs that lasted  $\geq 12$  weeks, had  $>30$  patients in each arm, and reported the percentage of patients who reached the goal of  $HbA_{1c} < 7\%$ . Eight of the 10 studies that fit these criteria enrolled insulin treatment-naïve patients. A greater percentage of patients treated with premix insulin analogs achieved  $HbA_{1c} < 7\%$  (46.5%) compared with patients treated with basal insulin (36.1%) (odds ratio 1.88 [95% CI 1.38–2.55],  $P = 0.0012$ ). However, treatment with premix insulin analogs, compared with basal analogs, used two instead of one injection per day. Compared with basal analogs, premix insulin analogs use was associated with an increased incidence of minor hypoglycemia (mean difference 0.34 events/patient/30 days [range 0–0.69],  $P = 0.05$ , and after the use of mixed-effects model, with estimates adjusted for the correlation within studies and heterogeneity between studies, mean difference 0.28 events/patient/30 days [0.10–0.45],  $P = 0.006$ ). Weight gain averaged 2.42 kg in the premix group compared with 1.44 kg in the basal group (between-groups difference of 1.0 kg [range 0.28–1.73],  $P = 0.01$ ). Major hypoglycemia events were very low and similar between groups. The previously mentioned studies had surrogate markers of  $HbA_{1c}$  as their primary end point; more information is required regarding the clinical outcome of controlled fasting versus postprandial glucose levels. Only one long-term study, the Hyperglycemia and its Effect After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus (HEART 2D), compared cardiovascular outcomes in post-myocardial infarction patients treated with basal versus prandial or premix insulin (49). The goal of the study was to examine the effect on cardiovascular outcomes of decreasing fasting versus postprandial glucose while maintaining similar  $HbA_{1c}$  levels. The study did not demonstrate any difference in cardiovascular outcomes between the treatment strategies. The HEART 2D trial ended prematurely for futility; however, classification and regression tree was used to identify baseline subgroups with potential treatment differences (50). Classification and regression tree estimated the age of  $>65.7$  years

to best predict the difference in time to first event. In the subgroup aged  $>65.7$  years (prandial,  $n = 189$ ; basal,  $n = 210$ ), patients treated with prandial regimen had a significantly longer time to first event, and a lower proportion experienced a first event ( $n = 56$  [29.6%] vs.  $n = 85$  [40.5%]; hazard ratio 0.69 [95% CI 0.49–0.96];  $P = 0.029$ ) despite similar  $HbA_{1c}$  levels (50). The results of the previously mentioned meta-analysis, as well as other trials (35,51), suggest that most type 2 diabetic patients in whom insulin treatment is initiated will benefit most from basal insulin because of the relative ease of treatment and the reduced risk of hypoglycemia and weight gain compared with other insulin treatment regimens (3). The results of the previously quoted studies (35–51) were not conclusive in demonstrating that one insulin regimen is better than the other. Owing to their design and size, most studies are not able to define which subgroups of patient will benefit more from the premix or basal insulin regimen. However, since most studies demonstrated higher efficacy of premix insulin in the entire population (36–42), it can be assumed that in the subgroup of patients where despite high  $HbA_{1c}$  the fasting plasma glucose is relatively low, postprandial glucose is relatively high, and therefore, premix insulin regimen in this subgroup might demonstrate even better efficacy and safety than in the entire population. The 4-T study (40) demonstrated the superior efficacy of premix insulin analogs over basal insulin in achieving glucose control in the entire study population but not in the group with  $HbA_{1c} < 8.5\%$ ; therefore, it can be assumed that in patients with  $HbA_{1c} > 8.5\%$  the stronger effect of premix insulin over basal insulin in  $HbA_{1c}$  reduction is even more dominant.

To the best of our medical judgment, there may be three important exceptions to initiating insulin therapy with basal insulin. The first involves patients with high  $HbA_{1c}$  ( $>8.5\%$ ) who may not be able to reach their  $HbA_{1c}$  goal solely with basal insulin, since they also need insulin “cover” for their postprandial glucose. Most RCTs and meta-analyses have demonstrated the superiority of premix insulin analogs over basal insulin in reducing  $HbA_{1c}$  (36–42), including in patients with  $HbA_{1c} > 10\%$  (36). In this high-risk patient population an increase in weight gain and mild hypoglycemia with premix insulin analogs might be justified. Ideally, patients who are very far from proper glucose control should be considered for basal-bolus treatment.


However some of these patients cannot adhere to a complex insulin regimen such as basal-bolus regimen (due to advanced age, need for assistance with injection, lack of support, etc.). Insulin nonadherence, including injection omission, is common among adults with type 2 diabetes (52–55) and correlates with poorer glucose control; however, a direct comparison of compliance among premix insulin analogs versus basal-bolus-treated patients is lacking.

The second exception is patients with lower compliance, who are often more hesitant to titer their insulin doses and therefore may benefit more from initiation of premix insulin analogs usually initiated with larger doses of insulin, requiring less titration in order to reach goals.

The third exception includes patients with relatively low ( $<150$  mg/dL) fasting or preprandial plasma glucose and a relatively high  $HbA_{1c}$ , suggesting high postprandial hyperglycemia. The family physician’s long-term and multifaceted acquaintance with the patient may be an advantage for recognizing/identifying these three specific groups of patients. This approach to initiating insulin therapy is summarized in Fig. 1.

#### When basal insulin is not enough: premix insulin analogs versus basal plus and basal-bolus regimens

Glucose control can be referred to as a three-part challenge: control of fasting glucose, postprandial glucose, and



**Figure 1**—Rationale for initiating basal versus premix insulin analogs. GLP-1, glucagon-like peptide 1; FPG, fasting plasma glucose.



Table 1—Which patient should be offered a premix versus basal-bolus/basal plus regimen?

Premix insulin analogs	Basal plus/basal bolus
Patient preference	Type 1 diabetes (any age)
Older age	Younger age
Need assistance with injections	Highly motivated and compliant
Organized lifestyle	Active lifestyle
Two meals a day or evening main meal	High variability in eating habits

HbA<sub>1c</sub>. While basal insulin analog doses can usually be titrated until they control fasting plasma glucose levels, a large proportion of patients will immediately or eventually need a more complete replacement of insulin that also includes prandial insulin (56,57). Postprandial insulin deficiency can be addressed in some patients using glucagon-like peptide 1 analogs; for others, however, this treatment might be insufficient, intolerable, or simply unaffordable. According to the ADA/EASD position statement (1), “glucose-lowering effects should be balanced with the convenience of the regimen, in the context of an individual’s specific therapy goals.” The addition of prandial/mealt ime insulin to basal insulin should be considered when fasting glucose is at target, or cannot be achieved, while HbA<sub>1c</sub> is above target for 3–6 months after basal insulin titration (1). When basal insulin therapy is not enough, ideally, the family physician should either intensify insulin therapy by him/herself or, if lacking time or a support team, consider referring the patient to an endocrinologist/diabetologist for further evaluation and consideration of the different possible treatment strategies. It is important to note that availability of such a consultation differs greatly among regions, countries, and health insurance systems. The frequency of such consultations might also be sparse; therefore, the active involvement of the family physician and his/her team in the treatment of diabetic patients should not be underestimated at any stage.

The three main options available for patients who need further intensification of their insulin regimen are the addition of rapid-acting insulin with one of the daily meals (basal plus regimen); the addition of rapid insulin with two–three daily meals (basal bolus); or a switch to premix insulin before two–three daily meals (57,58). Is there a preferred way to intensify insulin therapy?

The meta-analysis of Giugliano et al. (48) included only three RCTs comparing premix insulin analogs with basal-bolus


regimens that met the above-mentioned quality measurements (study duration >12 weeks, sample size >30 in each arm, and report of the proportion of patients reaching HbA<sub>1c</sub> <7%). They compared premix insulin analogs to basal-bolus regimens in non-insulin-naïve patients. The meta-analysis concluded that patients treated with premix insulin analog compared with basal-bolus regimen had a lower chance of reaching the HbA<sub>1c</sub> goal: 50.8 vs. 63.5% (odds ratio 0.57 [95% CI 0.36–0.9],  $P = 0.034$ ), while there was no evidence of difference in incidence of hypoglycemia and weight gain between the two regimens. It is reassuring to note the low overall incidence of hypoglycemic events, almost all of which were entirely mild hypoglycemia, in the entire meta-analysis—0.4 events/patient/30 days (range 0–4.71 [interquartile range 0.3–1.0])—and the limited weight gain (1.0 and 1.9 kg in the premix and prandial groups, respectively). It is not surprising that treatment with four to five daily insulin injections was more effective in achieving HbA<sub>1c</sub> <7% than two to three injections per day; however, when considering basal-bolus versus premix insulin regimens we must keep in mind the important difference between clinical trials and real-world patients and protocols. Patients in clinical studies are preselected for better compliance and are more closely followed up than is feasible in a real-world scenario. The question is whether similar results could be achieved in a real-world setting and especially in the primary care setting, where resources are often limited; this question has not yet been resolved. It is important to remember that insulin intensification is not always a single step or in one-way direction. As stated in the section of the ADA/EASD position statement (1) regarding insulin intensification, if treatment with premix insulin analogs is unsuccessful in achieving glucose control goals after proper titration of this regimen was done, a progression to basal-bolus regimen is possible. On the other hand, if patient compliance with lifestyle modification improves, simplification of insulin regimen is sometimes possible.

An important issue in real-world insulin treatment is the adherence to regimen. Nonadherence to insulin therapy is associated with both worse glycemic control (52,59) and increased risk of diabetes-related microvascular complications (53). Omitting insulin dose is common among type 2 diabetic patients (52–55,59) and might be even more common than among type 1 diabetic patients (52). Nonadherence to insulin therapy was found to be significantly and independently associated with two aspects of injection burden: having to plan daily activities around insulin injections and injections interfering with activities of daily life (54). In a recent telephone survey (55) that included 1,530 insulin-treated adults (110 type 1 diabetic and 1,420 type 2 diabetic) from eight countries, 35% of patients reported  $\geq 1$  day of insulin omission/nonadherence (average 3 days) in the past month. Insulin nonadherence varied widely across countries (20–44%) (55).

One option tested to ease the intensification of insulin treatment for patients in whom basal insulin therapy did not achieve glucose control target are the addition of one shot of rapid-acting insulin per day with one of the meals (basal plus) instead of adding two or more injections of rapid-acting insulin per day (basal bolus). However, even in the well-controlled setting of a treat-to-target clinical trial (60) over 1 year, >70% of the patients who were initiated on basal plus were shifted to basal-bolus regimen. Therefore, switching from basal insulin to basal plus instead of basal bolus may ease the change for the patient, but both the clinician and the patient should be aware of the possibility that the treatment will need to be further intensified within a short time to basal plus regimen in order to achieve glycemic goals. When deciding whether to put a patient on a basal plus regimen, the clinician should ensure that the patient is able to manage his/her diabetes with all the complexity of basal-bolus treatment: multiple daily injections and multiple daily glucose monitoring. Deciding which patient will benefit from the more complex basal-bolus regimen and will be able to comply with its demands involves complex and important clinical judgment. The family physician, who is more familiar with the patient, is in a good position to evaluate which regimen will be the best for the patient. Some points to help decision making are summarized in Table 1.

In conclusion, intensification of basal insulin to premix insulin analogs instead





**Figure 2**—Initiation and intensification of premix insulin analogs.

of basal bolus is suitable for 1) patients in whom we are satisfied with less strict diabetes control, 2) patients who cannot comply with basal-bolus treatment, and 3) patients with a well-organized daily life. In these patients, treatment with premix insulin analogs can help achieve acceptable and safe glucose control while allowing them an easier way to manage their disease. Figure 2 presents guidance for physicians on changing from basal insulin to a premix insulin analog including titration to goal.

## Conclusions

The family physician should initiate insulin treatment, when required, in a timely manner. The primary care health team should be involved in all the steps of insulin treatment: setting glucose control goal, initiating insulin therapy, titration of insulin dose, and intensification of treatment regimen if necessary. The endocrinologist/diabetologist should be available for advice and guidance as needed. Basal insulin is preferable when adding insulin therapy to antidiabetes drugs. Three exceptions that can often be identified by the family physician are patients with relatively low fasting or preprandial glucose ( $<150$  mg/dL) despite high  $HbA_{1c}$ , patients with difficulty in compliance with the high demands of basal-bolus treatment, and patients in whom self-titration might not be feasible (Fig. 1). When basal insulin fails to achieve the target in spite of titration, the family physician should proceed to insulin

intensification and consider consulting with an endocrinologist/diabetologist. The three common regimens used to intensify insulin therapy are premix, basal plus, and basal bolus. Most patients who begin a basal plus regimen will eventually need a basal-bolus regimen; therefore, basal plus regimen should be initiated if the treating physician decides that the patient will be able to adhere to a basal-bolus regimen. Basal bolus most closely resembles physiological insulin secretion; however premix insulin analogs can be a good option with less complicated and demanding glucose monitoring and injection schedule. Often, family physicians have a long-standing and more personal understanding of their patients and are in a good position to select the appropriate patients for basal plus/basal-bolus versus premix treatment. In order to properly treat their patients with insulin, the family physician should be knowledgeable and have enough time, support (nurse, dietitian, etc.), and incentive to accomplish this task. The rule should be tailoring insulin treatment to suit the patient and not the other way around.

**Acknowledgments**—I.R. is on the advisory boards of Novo Nordisk, AstraZeneca, Bristol-Myers Squibb, Merck Sharp & Dohme, and Eli Lilly; is a consultant for AstraZeneca, Bristol-Myers Squibb, Johnson & Johnson, Eli Lilly, and Israeli firms (Andromeda, HealOr, Insuline, TransPharma, and Teva); and sits on the speakers bureaus of Eli Lilly, Novo Nordisk, AstraZeneca, Roche, and Johnson & Johnson. O.M. sits on the speakers bureaus of Novo

Nordisk, Eli Lilly, Sanofi, Novartis, and Merck Sharp & Dohme; sits on the advisory boards of Novo Nordisk, Eli Lilly, Sanofi, and Novartis; and receives grants paid to Hadassah University Hospital as a study physician by AstraZeneca and Bristol-Myers Squibb. No other potential conflicts of interest relevant to this article were reported.

O.M. researched and wrote and edited the manuscript. I.R. edited and reviewed the manuscript. O.M. and I.R. are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

## References

1. Inzucchi SE, Bergenstal RM, Buse JB, et al.; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care* 2012;35:1364–1379
2. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. *Diabetes Res Clin Pract* 2011;94:311–321
3. Nathan DM, Buse JB, Davidson MB, et al.; American Diabetes Association; European Association for the Study of Diabetes. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetologia* 2009;52:17–30
4. IDF Clinical Guidelines Task Force. *Global Guideline for Type 2 Diabetes*. Brussels, International Diabetes Federation, 2005
5. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. *Endocr Pract* 2009;15:540–559
6. Berard LD, Booth G, Capes S, Quinn K, Woo V. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. *Canadian Journal of Diabetes* 2008;32:S1–S201
7. *Type 2 Diabetes: the Management of Type 2 Diabetes: NICE Clinical Guideline 87*. London, National Institute for Health and Clinical Excellence, 2009. Available from [www.nice.org.uk/CG87](http://www.nice.org.uk/CG87). Accessed 27 February 2013
8. Home P, Mant J, Diaz J, Turner C; Guideline Development Group. Management of type 2 diabetes: summary of updated NICE guidance. *BMJ* 2008;336:1306–1308



9. Brange J, Owens DR, Kang S, Völund A. Monomeric insulins and their experimental and clinical implications. *Diabetes Care* 1990;13:923–954
10. Jacobsen LV, Søgaard B, Riis A. Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart. *Eur J Clin Pharmacol* 2000;56:399–403
11. Weyer C, Heise T, Heinemann L. Insulin aspart in a 30/70 premixed formulation. Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture. *Diabetes Care* 1997;20:1612–1614
12. Kapitza C, Rave K, Ostrowski K, Heise T, Heinemann L. Reduced postprandial glycaemic excursion with biphasic insulin Aspart 30 injected immediately before a meal. *Diabet Med* 2004;21:500–501
13. Warren ML, Conway MJ, Klaff LJ, Rosenstock J, Allen E. Postprandial versus preprandial dosing of biphasic insulin aspart in elderly type 2 diabetes patients. *Diabetes Res Clin Pract* 2004;66:23–29
14. Abrahamian H, Ludvik B, Schernthaner G, et al. Improvement of glucose tolerance in type 2 diabetic patients: traditional vs. modern insulin regimens (results from the Austrian Biaspart Study). *Horm Metab Res* 2005;37:684–689
15. Boehm BO, Home PD, Behrend C, Kamp NM, Lindholm A. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patients. *Diabet Med* 2002;19:393–399
16. Kilo C, Mezitis N, Jain R, Mersey J, McGill J, Raskin P. Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin. *J Diabetes Complications* 2003;17:307–313
17. Schmoelzer I, de Campo A, Pressl H, et al. Biphasic insulin aspart compared to biphasic human insulin reduces postprandial hyperlipidemia in patients with Type 2 diabetes. *Exp Clin Endocrinol Diabetes* 2005;113:176–181
18. Velojic-Golubovic M, Mikic D, Pesic M, Dimic D, Radenkovic S, Antic S. Biphasic insulin aspart 30: better glycemic control than with premixed human insulin 30 in obese patients with Type 2 diabetes. *J Endocrinol Invest* 2009;32:23–27
19. Malone JK, Yang H, Woodworth JR, et al. Humalog Mix25 offers better mealtime glycemic control in patients with type 1 or type 2 diabetes. *Diabetes Metab* 2000;26:481–487
20. Coscelli C, Iacobellis G, Calderini C, et al. Importance of premeal injection time in insulin therapy: Humalog Mix25 is convenient for improved post-prandial glycemic control in type 2 diabetic patients with Italian dietary habits. *Acta Diabetol* 2003;40:187–192
21. Fakhoury WK, Richter H, Christensen TE. Real-life dosage and clinical efficacy of biphasic insulin preparations in patients with type 2 diabetes. *Adv Ther* 2010;27:859–869
22. Iwamoto Y. A randomised, multicentre trial of biphasic insulin aspart versus biphasic human insulin in type 2 diabetes (Abstract). *Diabetologia* 2003;46:A270
23. Boehm BO, Vaz JA, Brøndsted L, Home PD. Long-term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetes. *Eur J Intern Med* 2004;15:496–502
24. Qayyum R, Bolen S, Maruthur N, et al. Systematic review: comparative effectiveness and safety of premixed insulin analogues in type 2 diabetes. *Ann Intern Med* 2008;149:549–559
25. Lasserson DS, Glasziou P, Perera R, Holman RR, Farmer AJ. Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses. *Diabetologia* 2009;52:1990–2000
26. Singh SR, Ahmad F, Lal A, Yu C, Bai Z, Bennett H. Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. *CMAJ* 2009;180:385–397
27. Davidson JA, Liebl A, Christiansen JS, et al. Risk for nocturnal hypoglycemia with biphasic insulin aspart 30 compared with biphasic human insulin 30 in adults with type 2 diabetes mellitus: a meta-analysis. *Clin Ther* 2009;31:1641–1651
28. Hirsch IB. Insulin analogues. *N Engl J Med* 2005;352:174–183
29. Hauber A, Gale EAM. The market in diabetes. *Diabetologia* 2006;49:247–252
30. Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naïve patients. *Diabetes Care* 2006;29:554–559
31. Peyrot M, Rubin RR, Lauritzen T, et al.; International DAWN Advisory Panel. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. *Diabetes Care* 2005;28:2673–2679
32. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. *N Engl J Med* 2008;359:1577–1589
33. Gerstein HC, Bosch J, Dagenais GR, et al.; ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. *N Engl J Med* 2012;367:319–328
34. Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. *Diabetes Care* 2004;27:1535–1540
35. Vaag A, Lund SS. Insulin initiation in patients with type 2 diabetes mellitus: treatment guidelines, clinical evidence and patterns of use of basal vs premixed insulin analogues. *Eur J Endocrinol* 2012;166:159–170
36. Raskin P, Allen E, Hollander P, et al.; INITIATE Study Group. Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs. *Diabetes Care* 2005;28:260–265
37. Malone JK, Kerr LF, Campaigne BN, Sachson RA, Holcombe JH; lispro Mixture-Glargine Study Group. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. *Clin Ther* 2004;26:2034–2044
38. Malone JK, Bai S, Campaigne BN, Reviriego J, Augendre-Ferrante B. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes. *Diabet Med* 2005;22:374–381
39. Kazda C, Hülstrunk H, Helsing K, Langer F, Forst T, Hanefeld M. Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy. *J Diabetes Complications* 2006;20:145–152
40. Holman RR, Thorne KI, Farmer AJ, et al.; 4-T Study Group. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. *N Engl J Med* 2007;357:1716–1730
41. Robbins DC, Beisswenger PJ, Cieriello A, et al. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison. *Clin Ther* 2007;29:2349–2364
42. Buse JB, Wolffbuttel BH, Herman WH, et al. DURABILITY of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes. *Diabetes Care* 2009;32:1007–1013
43. Kann PH, Wascher T, Zackova V, et al. Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride. *Exp Clin Endocrinol Diabetes* 2006;114:527–532
44. Jacober SJ, Scism-Bacon JL, Zagar AJ. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents. *Diabetes Obes Metab* 2006;8:448–455
45. Strojek K, Bebakar WM, Khutsaane DT, et al. Once-daily initiation with biphasic



- insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT. *Curr Med Res Opin* 2009;25:2887–2894
46. Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Järvinen H. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. *Diabetes Care* 2005;28:254–259
47. Sun P, Wang R, Jacober S. The effectiveness of insulin initiation regimens in patients with type 2 diabetes mellitus: a large national medical records review study comparing a basal insulin analogue to premixed insulin. *Curr Med Res Opin* 2007;23:3017–3023
48. Giugliano D, Maiorino MI, Bellastella G, Chiodini P, Ceriello A, Esposito K. Efficacy of insulin analogs in achieving the hemoglobin A1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. *Diabetes Care* 2011;34:510–517
49. Raz I, Wilson PW, Strojek K, et al. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. *Diabetes Care* 2009;32:381–386
50. Raz I, Ceriello A, Wilson PW, et al. Post hoc subgroup analysis of the HEART2D trial demonstrates lower cardiovascular risk in older patients targeting postprandial versus fasting/premeal glycemia. *Diabetes Care* 2011;34:1511–1513 DOI: 10.2337/dc10-2375
51. Ilag LI, Kerr L, Malone JK, Tan MH. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison. *Clin Ther* 2007;29:1254–1270
52. Donnelly LA, Morris AD, Evans JM; DARTS/MEMO collaboration. Adherence to insulin and its association with glycaemic control in patients with type 2 diabetes. *QJM* 2007;100:345–350
53. Cramer JA, Pugh MJ. The influence of insulin use on glycemic control: How well do adults follow prescriptions for insulin? *Diabetes Care* 2005;28:78–83
54. Peyrot M, Rubin RR, Kruger DF, Travis LB. Correlates of insulin injection omission. *Diabetes Care* 2010;33:240–245
55. Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Factors associated with injection omission/non-adherence in the Global Attitudes of Patients and Physicians in Insulin Therapy study. *Diabetes Obes Metab* 2012;14:1081–1087
56. Jermendy G. Optimal insulin treatment for patients with type 2 diabetes: basal or prandial insulin supplementation? *Diabetes Res Clin Pract* 2006;74S(Suppl.):S20–S29
57. Raccach D, Bretzel RG, Owens D, Riddle M. When basal insulin therapy in type 2 diabetes mellitus is not enough—what next? *Diabetes Metab Res Rev* 2007;23:257–264
58. Raccach D. Options for the intensification of insulin therapy when basal insulin is not enough in type 2 diabetes mellitus. *Diabetes Obes Metab* 2008;10(Suppl. 2):76–82
59. Broadbent E, Donkin L, Stroh JC. Illness and treatment perceptions are associated with adherence to medications, diet, and exercise in diabetic patients. *Diabetes Care* 2011;34:338–340
60. Meneghini L, Mersebach H, Kumar S, Svendsen AL, Hermansen K. Comparison of 2 intensification regimens with rapid-acting insulin aspart in type 2 diabetes mellitus inadequately controlled by once-daily insulin detemir and oral antidiabetes drugs: the step-wise randomized study. *Endocr Pract* 2011;17:727–736